|
Video: What is a Stock Split?
|
|
Tharimmune is engaged in the development of therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treating cancers. Co.'s product candidate is HSB-1216, an IMCD modulator, targeting solid tumors. Co.'s HSB-888, is a dual-loaded IMCD inducer coupled with its anthracycline analogue. Co.'s HSB-510 is a bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6. Co. owns HSB-114, which is a immunotherapeutic agent that delivers tumor necrosis factor-alpha gene into cancer cells. According to our THAR split history records, Tharimmune has had 1 split. | |
|
Tharimmune (THAR) has 1 split in our THAR split history database. The split for THAR took place on November 21, 2023. This was a 1 for 25 reverse split, meaning for each 25 shares of THAR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as Tharimmune conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the THAR split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tharimmune shares, starting with a $10,000 purchase of THAR, presented on a split-history-adjusted basis factoring in the complete THAR split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/13/2022 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$68.75 |
|
End price/share: |
$0.37 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.46% |
|
Average Annual Total Return: |
-89.88% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$53.66 |
|
Years: |
2.28 |
|
|
|
Date |
Ratio |
11/21/2023 | 1 for 25 |
|
|